Belite Bio Inc - Adr (BLTE)
$50.9
Performance
- $50.90$51.43$50.90
0.0%
Downside
Day's Volatility :1.04%
Upside
1.04%
- $28.51$51.15$50.90
43.99%
Downside
52 Weeks Volatility :44.26%
Upside
0.49%
Returns
| Period | Belite Bio Inc - Adr | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 4.92% | 5.0% | 0.0% |
6 Months | 27.54% | 5.9% | 0.0% |
1 Year | 69.97% | 16.6% | 0.0% |
3 Years | 248.05% | 18.9% | -21.4% |
Highlights
Market Capitalization | 1.6B |
Book Value | $3.74 |
Earnings Per Share (EPS) | -1.23 |
Wall Street Target Price | 56.75 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -25.62% |
Return On Equity TTM | -41.44% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -36.5M |
Diluted Eps TTM | -1.23 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.17 |
EPS Estimate Next Year | -0.96 |
EPS Estimate Current Quarter | -0.25 |
EPS Estimate Next Quarter | -0.26 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 11.49%
Technicals Summary
Sell
Neutral
Buy
Belite Bio Inc - Adr is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Belite Bio Inc - Adr | 4.34% | 27.54% | 69.97% | 248.05% | 248.05% |
 Regeneron Pharmaceuticals, Inc. | -11.53% | 7.92% | 21.76% | 83.48% | 256.87% |
 Novo Nordisk A/s | -12.73% | -9.68% | 25.05% | 134.03% | 343.37% |
 Alnylam Pharmaceuticals, Inc. | 5.86% | 71.74% | 59.21% | 32.07% | 248.13% |
 Vertex Pharmaceuticals Incorporated | -3.35% | 12.64% | 28.18% | 152.92% | 164.64% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Belite Bio Inc - Adr | NA | NA | NA | -1.17 | -0.41 | -0.26 | NA | 3.74 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.76 | 38.76 | 1.75 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Belite Bio Inc - Adr | Buy | $1.6B | 248.05% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 256.87% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $512.4B | 343.37% | 38.76 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.4B | 248.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $117.5B | 164.64% | 32.84 | -4.74% |
Institutional Holdings
Armistice Capital, LLC
0.48%State Street Corp
0.05%Point72 Asset Management, L.P.
0.02%Geode Capital Management, LLC
0.02%HRT FINANCIAL LLC
0.02%Virtus ETF Advisers LLC
0.01%
Company Information
belite bio inc is a san diego based clinical stage biopharmaceutical drug development company targeting untreatable age-related metabolic diseases, including macular degeneration, liver disease and diabetes. developed from our anti-rbp4 technology platform, our lead candidate, lbs-008, is currently in a phase i clinical trial for dry age-related macular degeneration and its juvenile form, stargardt disease. lbs-008 has received orphan drug status in the us and europe, as well as rare pediatric disease status in the us.
Organization | Belite Bio Inc - Adr |
Employees | 20 |
CEO | Dr. Yu-Hsin Lin M.B.A., Ph.D. |
Industry | Healthcare |
